CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,674 | +117.5% | 3,755 | +31.8% | 0.01% | +200.0% |
| Q2 2023 | $51,339 | +12.2% | 2,849 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $45,755 | -21.6% | 2,849 | -10.7% | 0.00% | -33.3% |
| Q4 2022 | $58,395 | -6.8% | 3,191 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $62,671 | +5.3% | 3,191 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $59,512 | -1.8% | 3,191 | +15.5% | 0.00% | +50.0% |
| Q1 2022 | $60,626 | -82.0% | 2,762 | -76.6% | 0.00% | -60.0% |
| Q4 2021 | $335,948 | +65.2% | 11,825 | +22.4% | 0.01% | +66.7% |
| Q3 2021 | $203,343 | +11.7% | 9,660 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $182,091 | +55.0% | 9,660 | +25.7% | 0.00% | +50.0% |
| Q1 2021 | $117,442 | -5.3% | 7,686 | -12.6% | 0.00% | 0.0% |
| Q4 2020 | $124,055 | -10.0% | 8,792 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $137,771 | -10.6% | 8,792 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $154,036 | +151.1% | 8,792 | +110.7% | 0.00% | +200.0% |
| Q1 2020 | $61,343 | -41.4% | 4,173 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $104,701 | +352.8% | 4,173 | +351.1% | 0.00% | – |
| Q2 2019 | $23,125 | – | 925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |